The Influence of Docetaxel Schedule on Treatment Tolerability and Efficacy in Patients with Metastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials

BMC Cancer

Weekly docetaxel is associated with a lower risk of neutropenia, febrile neutropenia and neuropathy than the three-weekly docetaxel schedule in metastatic breast cancer patients. However, the risk of onycholysis, epiphora, and treatment discontinuation seems increased with weekly administration. No significant differences in efficacy outcomes were found. Weekly docetaxel might be an alternative for patients at risk for developing neutropenia.